BioCentury
ARTICLE | Clinical News

Boniva Ibandronate regulatory update

July 15, 2013 7:00 AM UTC

Chugai and Taisho said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for monthly IV Bonviva ibandronate to treat osteoporosis. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate that inhibits osteoclast-mediated bone resorption in Japan (see BioCentury, Sept. 18, 2006). The partners are developing a monthly oral formulation, which is in Phase III testing. Chugai is majority owned by Roche. ...